ReInvent Pharma

Reinventing Existing Drugs for New Hope in Fighting Cancer

ABOUT US

Patients are our number one priority. Founded in 2018, Reinvent Pharma’s goal is to improve the life of cancer patients by making immuno and targeted therapies more effective and affordable to all. These revolutionary new therapies are replacing years of chemo and radiation as the only viable option for most patients to treat cancer.

However, still only a minority of cancer patients benefit. These new technologies are suffering from major clinical and commercial unmet needs and as a result therapies aren’t being exploited to reach their full effectiveness.

Reinvent Pharma is addressing the gap. Our passion-driven team of experts are developing a new type of treatment based on a combination of FDA approved drugs to improve the effectiveness and response of these new therapies. Our technology broadens the reach of these new treatments to more cancer patients and type as well as decreasing the financial burden associated with them.

Initially, we are focused on solid tumors like, liver, pancreatic, bile duct and brain cancer because these cancer types are clinically challenging and have yet to care immune and targeted therapeutic success. Our novel re-positioning combination approach will take the current revolution of therapy across the finish line by offering rapid development and integrated tools that select optimal solutions so, that all cancer patients can profit.

Currently the gold standard of immunne based therapies are drugs within the family of immune check point inhibitors (ICIs) effecting only 20-30% of treated patients having immunogenic tumors (“hot” tumors and about 2-3% of treated patients caring a nonimmunogenic tumors (“cold” tumors).

To answer the therapeutic efficiency gap that these new advances are facing, ReInvent Pharm is developing a simple solution based on novel Fixed Dose Combinations of “cabinet” drugs for an “off-label” use. This address the clinical unmet needs in a short period of time by increasing proportion and duration of clinical response in patients with both cold and hot tumors.

OUR STRATEGY

Reinvent developmental strategy is based on 3 pillars

I.

Rapid developmental and integration of in silico, in vitro and in vivo tools to select the optimal combinations for full clinical development.

II.

Selected drug combinations are formulated in a FDC form and this new drug product activity is being tested in clinical phase utilizing accelerate 505(b)(2) pathway and breakthrough technologies pathway for FDA approval.

III.

Partnerships with relevant and leading pharma companies to ensure efficient clinical development of selected effective drug-combinations and to bring a timely and cost efficient treatment to the market.

OUR TEAM

ReInvent Pharma's passion-driven team of experts and key personel.

Dr. Itschak Lamensdorf

Founder and CEO

Dr. Lamensdorf brings over 20 years of experience in company

management and early drug development. Prior to founding Reinvent Pharma, Dr. Lamensdorf was the founder and served as CEO and CSO in several companies, including Pharmaseed, Alvit, 4P Pharma, Trinutra and Thrombotech. Dr. Lamensdorf earned his PhD in Pharmacology from the Technion Institute of technology and his B.S. and M.Sc. in Clinical Pharmacy from the Hebrew University of Jerusalem Medical School. He held postdoctoral positions at the National Institute of Neurological Disorders and Stroke of the National Institute of Health (NIH), Bethesda, Maryland and at the Molecular Genetics Department of Israel’s Weizmann Institute of Science.

Dr. Joseph Schwarz

Formulation Expert

Dr. Schwarz is an industrial expert in Pharmaceutical technology and formulation development. Dr. Schwartz has more than 20 years of pharmaceutical R&D experience within the fields of oral sustained release formulations. Prior to joining Reinvent Pharma, Dr. Schwarz served as Chief Scientist in several successful companies, such as Alpharx, Pharcon and Teva. He worked on the design, development and manufacturing of generic and brand oral pharmaceutical products with the focus on anti-inflammatory drugs. Dr. Schwartz received his PhD in Organic Chemistry from Zelinsky Organic Chemistry Institute Academy of Science, Russia. He has more than 40 publications and 8 patents.

Dr. Robert E. Kast

Clinical and Pre-clinical off- label Expert

Dr. E. Kast has more than 20 years of medical practice and academic research. With more than 140 publications, Dr. Kast is recognized as a world expert in the field of “off-labeled drug repurposing” for Glioblastoma Multifore, breast cancer and ovarian cancers. Dr. Kast is a member of the European Association of Neuro-Oncology, Vermont Medical Society and Society for Neuro-Oncology. Dr. Kast completed his studies at the Faculty of Medicine, University of Copenhagen, Denmark and received his MS in Immunology from University of Copenhagen, Denmark..

Avshalom Shalev

Head of Pharmaceutical R&D

Avshalom is a seasoned pharmaceutical professional with 30 years of experience in the production of oral solid dosage forms. He is a subject matter expert in the various technologies available to the pharmaceutical industry, as well as how to manage product technology transfer between production sites, including transfer from transnational R&D to clinical grade production. Avshalom has held several managerial positions at leading pharmaceutical companies such as TEVA and Chartwell Pharmaceuticals and has played pivotal roles in roles in complex formulation and analytical developments there. Avshalom holds a Bachelor’s of Science in Geographic chemistry from Bar Ilan University.

Dr. Howard Bruckner

Medical Adviser

Dr. Bruckner is the founder of the Bruckner Oncology Clinic,and The MZB Foundation for Cancer Research. He has over 40 years of clinical and research experience and is an expert in drug interaction and integrative personalized treatment. Dr. Bruckner has vast experience in drug development, integration of standard and off-label drugs within personalized chemo, and targeted and immuno therapies. He co-authored over 150 peer-reviewed articles, numerous books and abstracts. Dr. Bruckner also served as an NIH Associate Director Special Assistant and held the academic rank of Professor at the Mount Sinai School of Medicine and State University of New York (SUNY) Downstate Brooklyn NY School of Medicine. Dr. Bruckner earned his MD from Albert Einstein College of Medicine, postdoctoral training at both Albert Einstein College of Medicine and Yale University School of Medicine.